组蛋白去乙酰化酶HDAC2突变体构建及其SUMO修饰E3连接酶功能研究

目的:针对人源HDAC2外显子拼接功能区(CDS)基因,运用双管法突变体构建技术,构建HDAC2去乙酰化酶功能失活的片段缺失与关键位点突变体,检测突变体的SUMO化修饰E3连接酶功能活性,探究此HDAC2新功能是否受到其固有的去乙酰化酶功能的影响.方法:设计HDAC2 100-322位氨基酸密码子缺失的片段突变体引物与142位H→A点突变体引物,利用HDAC2的pcDNA3.1真核表达质粒为模板,通过耐热Fusion酶PCR反应双管扩增相应的单链DNA,并经退火、模板酶切、乙醇纯化、感受态转化、抗性平板筛选、测序鉴定获得两种HDAC2去乙酰化酶功能失活的pcDNA3.1真核表达质粒.免疫印迹检测突变体质粒在细胞中的表达,荧光素酶(LUC)报告基因实验检测其SUMO化修饰E3连接酶功能活性.结果:成功构建HDAC2去乙酰化功能失活的片段缺失突变体pcDNA3.1/HDAC2 (DEL 100-322AA)与关键位点突变体pcDNA3.1/HDAC2(142 H→A).C-myc标签的免疫印迹检测显示两种突变体在细胞中可稳定表达.将突变体转染进入三种细胞,LUC报告基因分析结果显示突变体仍具有E3连接酶功能活性.结论:HDAC2的E3连接酶功能不依赖于其去乙酰化酶活性,并且E3连接酶功能结构域位于其序列C端.     

LKB1抑制人巨细胞肺癌细胞的增殖和迁移侵袭、mTOR磷酸化与VEGF和MMP9表达

目的分析肝激酶B1(liver kinase B1,LKB1)对人巨细胞肺癌(the people giant cell lung cancer,PGCL3)细胞增殖、迁移、侵袭的影响及其机制。方法构建真核表达载体p CMV-LKB1,转染人巨细胞肺癌细胞。转染后48h,用免疫印迹法检测各组细胞LKB1蛋白表达水平,明确转染PGCL3效率。转染后每隔12h、连续72h检测LKB1对细胞增殖能力的影响;Transwell小室检测转染后各组细胞迁移、侵袭力。提取各组细胞蛋白检测基质金属蛋白酶2(matrix metalloproteinase 2,MMP2)、基质金属蛋白酶9(matrix metalloproteinase 9,MMP9)、雷帕霉素靶蛋白(mammalian target of rapamycin,m TOR)和血管内皮生长因子(vascular endothelial growth factor,VEGF)的表达水平。结果 p CMV-LKB1经PCR、双酶切及DNA测序鉴定后,证实目的基因片段插入方向正确,核酸序列与NCBI公布的LKB1的核酸序列一致;免疫印迹分析显示,转染p CMV-LKB1的PGCL3细胞中LKB1表达水平明显增高,表明p CMV-LKB1构建成功。增殖曲线分析和5-乙炔基-2,脱氧嘧啶核苷(5-ethynyl-2,-deoxyuridine,Ed U)检测显示,转染p CMV-LKB1能显著抑制PGCL3细胞的增殖;Transwell小室检测显示,过表达LKB1可显著抑制PGCL3细胞的迁移与侵袭;免疫印迹分析显示,过表达LKB1的PGCL3细胞其LKB1下游分子中总m TOR表达量不变,磷酸化m TOR(p-m TOR)水平降低,m TOR下游分子VEGF表达量也显著降低,迁移侵袭相关蛋白MMP2表达无变化,但MMP9水平显著降低。结论 LKB1可能通过下调PGCL3细胞p-m TOR水平,降低VEGF表达,从而抑制巨细胞肺癌细胞增殖,并可能通过下调金属基质蛋白酶MMP9的表达,降低巨细胞肺癌细胞迁移侵袭能力。     

CDX2基因高表达对胃癌细胞生物学行为的影响

目的探讨尾侧型同源转录因子-2(CDX2)基因过表达对胃癌BGC-823细胞增殖、迁移、凋亡等生物学特征的影响。方法采用脂质体转染法建立CDX2基因过表达的胃癌BGC-823稳定细胞株,分别采用RT-PCR、Western blotting和免疫细胞化学等方法检测转染重组表达载体pEGFP-C1/CDX2后,BGC-823细胞中CDX2基因及其蛋白的表达。MTT法检测CDX2基因过表达对细胞的增殖能力的影响;划痕实验检测CDX2过表达对细胞迁移能力的影响;流式细胞术检测CDX2过表达对细胞的凋亡的影响;应用基因芯片技术检测转染前后相关基因的差异表达。结果 RT-PCR及Western blotting检测结果显示,与对照组相比,转染pEGFP-C1/CDX2后,BGC-823细胞中CDX2基因和蛋白均呈高表达;CDX2过表达能明显降低转然组BGC-823细胞增殖能力和迁移能力;但对细胞凋亡影响不明显;基因芯片结果提示CDX2基因高表达能影响某些基因的表达。结论 CDX2过表达能明显抑制胃癌细胞增殖、降低迁移能力,提示CDX2在胃癌中可能发挥抑癌基因的作用。     

NDRG1基因过表达对胆囊癌GBS-SD细胞增殖及凋亡的影响

为了探讨N-myc下游调节基因1 (NDRG1)过表达对胆囊癌细胞系GBS-SD细胞增殖、迁移、侵袭和凋亡的影响及其可能的分子机制,本研究采用脂质体介导的重组真核表达质粒pEGFP-NDRG1-N3瞬时转染人胆囊癌GBS-SD细胞,Western blotting检测NDRG1蛋白的表达;MTT比色法和流式细胞术分别检测细胞增殖和细胞周期;Transwell实验检测细胞侵袭和迁移能力。GBS-SD细胞转染pEGFP-NDRG1-N3重组质粒后经表阿霉素(0.4μg/mL)诱导其凋亡,采用Hoechst 33258染色和流式细胞仪检测细胞凋亡;Western blotingt检测Bcl-2、Cleaved caspase-3和Bid蛋白的表达。MTT检测显示,NDRG1过表达组细胞在48 h和72 h的增殖速度均显著高于空载组和对照组(p0.05)。Transwell检测显示,与对照组和空载组相比,NDRG1过表达组细胞的侵袭和迁移能力明显增强。Hoechst 33258染色和流式细胞仪检测显示,经表阿霉素诱导细胞凋亡后,空载组细胞的凋亡率最高,NDRG1过表达组细胞的凋亡率低于空载组,但显著高于对照组。Western blotting检测显示,与对照组和空载组相比,NDRG1过表达组细胞中Bcl-2的表达明显上调,而Cleaved caspase-3和Bid的表达明显下调。本研究表明NDRG1基因过表达可显著促进胆囊癌细胞增殖、迁移、侵袭并抑制其凋亡,其分子机制可能是上调的NDRG1基因能有效调节与细胞凋亡相关基因的表达,从而发挥其介导作用。因此,NDRG1基因可能成为胆囊癌研究中一个新的治疗靶点。     

RNAi沉默STAT3基因对人大细胞肺癌细胞增殖的影响

旨在研究RNAi沉默STAT3基因对人大细胞肺癌NCI-H460细胞增殖的影响。针对STAT3基因mRNA设计合成5条短发夹DNA,构建重组SiRNA-ST3质粒(命名为SiRNA-ST3-1,2,3,4,N)。用重组质粒分别转染NCI-H460细胞,RT-PCR法检测转染24 h后STAT3 mRNA的表达;Western blotting法检测转染24 h和48 h后STAT3、pSTAT3蛋白表达;MTT法检测转染24 h、48 h、72 h后NCI-H460细胞增殖情况。结果显示,SiRNA-ST3载体构建成功。RT-PCR和Western blotting检测结果表明,NCI-H460细胞转染重组质粒SiRNA-ST3-2和SiRNA-ST3-3后STAT3基因mRNA转录和STAT3、pSTAT3蛋白表达都明显下降(P<0.05)。与未转染组比,SiRNA-ST3-2组和SiRNA-ST3-3组NCI-H460增殖能力24 h、48 h降低明显(P<0.05);与SiRNA-ST3-N组比,SiRNA-ST3-2组和SiRNA-ST3-3组NCI-H460增殖能力48 h降低明显(P<0.05)。由此证实,构建的重组质粒SiRNA-ST3-2、SiRNA-ST3-3能有效靶向沉默STAT3基因,并抑制人大细胞肺癌NCI-H460细胞的增殖能力。     

miR-125b慢病毒表达载体的构建及其对卵巢癌SKOV3细胞增殖和迁移的影响

构建并鉴定miR-125b慢病毒过表达载体,研究miR-125b对卵巢癌细胞增殖和迁移的影响及其可能机制。将PcR扩增的rniR-125b前体序列与经过酶切后的GP—SupersilencingVector进行连接,产生miR-125b重组慢病毒表达载体。将重组慢病毒载体质粒、pGag／Pol、pRev和pVSV-G共转染293T细胞,包装产生慢病毒。使用收获的病毒颗粒感染卵巢癌SKOV3细胞,嘌呤霉素筛选稳定感染细胞株;实时荧光定量PCR（Real．timeqPCR）检测miR-125b在SKV03细胞中的表达;Westernblot检测其潜在靶基因HER-2的表达：MTT实验和Transwell侵袭实验分别观察miR-125b过表达后SKOV3细胞增殖和迁移能力的改变。该研究成功构建miR-125b陧病毒过表达载体,感染卵巢癌SKOV3细胞后,能够过表达miR-125b,并抑制SKOV3细胞的增殖及迁移,降低潜在靶基因HER-2的表达。该研究证叽miR-125b能够抑制SKOV3细胞的增殖及迁移,并可能通过降低潜在靶基因HER-2的表达而实现。     

青藏高原黑果枸杞花青素对人肝癌细胞增殖和自噬的影响

探究黑果枸杞花青素在体外对人肝癌HepG2细胞增殖和自噬的影响。利用CCK-8法测定细胞活力,EdU和细胞划痕试验检测细胞增殖和迁移效果,RT-PCR和Western blot检测增殖和自噬相关基因的mRNA和蛋白表达。结果显示,黑果枸杞花青素可有效抑制人肝癌HepG2细胞的增殖和迁移;上调增殖因子(LATS1、LATS2和MOB1)和自噬因子(Beclin-1、LC3-Ⅱ和AMPK),并下调增殖因子YAP的mRNA水平;下调自噬因子p-mTOR和细胞周期因子CDK4,并上调自噬因子p-AMPK和LC3-Ⅱ的蛋白表达。由此推测黑果枸杞花青素可在体外抑制人肝癌HepG2细胞增殖和迁移,并促进人肝癌HepG2细胞发生自噬。     

芍药苷对结肠癌SW480细胞增殖、侵袭、迁移的影响

目的观察芍药苷对人结肠癌SW480细胞株增殖、侵袭、迁移的影响,探究其干预机制。方法含10%胎牛血清的DMEM/F12培养基常规培养人结肠癌SW480细胞株,CCK-8以及EdU-488法检测芍药苷对SW480细胞增殖的影响,Transwell小室检测芍药苷对SW480细胞侵袭、迁移的影响,Westernblot法检测beclin1、Bcl-2蛋白的表达。结果不同浓度芍药苷分别处理24h、48h、72h的结肠癌SW480细胞增殖活性受到显著抑制:相比较对照组,160μg/ml芍药苷处理48h后,SW480细胞内黄绿色荧光减弱,细胞增殖率显著下降,为(58.91±4.99)%;SW480细胞的侵袭细胞数、迁移细胞数显著下降:侵袭抑制率为26.50%,迁移抑制率为24.67%;beclin1蛋白表达高于对照组,Bcl-2蛋白表达低于对照组,beclin1与Bcl-2蛋白表达呈负相关。结论芍药苷能够抑制结肠癌SW480细胞增殖、侵袭和迁移,其机制可能通过抑制Bcl-2蛋白表达,上调beclin1蛋白的表达。     

miR-31-3p对横纹肌肉瘤细胞增殖和迁移的抑制作用和机制

该文研究了micro RNA-31-3p(mi R-31-3p)在横纹肌肉瘤细胞中的表达水平及其对细胞增殖和迁移的影响。通过定量RT-PCR法检测mi R-31-3p的表达水平。采用脂质体介导法将mi R-31-3p成熟体转染入横纹肌肉瘤细胞,通过MTS法、克隆形成实验、流式细胞技术和细胞功能分析仪分别检测细胞增殖能力、生长能力、周期和迁移能力。萤光素酶法和Western blot验证mi R-31-3p的靶基因。通过si RNA抑制STAT3检测其对横纹肌肉瘤细胞增殖和迁移的影响。结果显示,横纹肌肉瘤细胞中mi R-31-3p的表达水平较正常横纹肌组织显著下调。上调横纹肌肉瘤细胞中的mi R-31-3p能显著抑制细胞的增殖、克隆形成和迁移能力,并诱导细胞周期发生G1期阻滞。萤光素酶和Western blot结果显示, STAT3为mi R-31-3p的靶基因。下调STAT3的表达水平能够显著抑制RD细胞的增殖和迁移能力。总之, miR-31-3p可能通过下调STAT3来抑制横纹肌肉瘤细胞增殖和迁移。     

MFN1在肝癌转移中的调控作用研究

目的:探讨线粒体融合蛋白MFN1(mito-fusion 1)在肝癌转移中的作用及其机制。方法:1).采用免疫组化实验检测15对肝癌转移灶组织与原发灶组织中MFN1的表达,以明确肝癌转移时是否伴有MFN1表达的改变。2).采用si RNA (small interference RNA)下调肝癌细胞中MFN1的表达后,提高Transwell迁移实验和Transwell侵袭实验分别检测其迁移和侵袭能力,通过实时荧光定量PCR (Quantitative Real-time PCR,qRT-PCR)和Western blot实验分别检测基质金属蛋白酶1 (matrix metalloproteinase 1,MMP1)、MMP2、MMP7及MMP9的m RNA和蛋白表达。结果:1)肝癌转移灶组织中MFN1表达显著低于原发灶组织(P0.05)。2).下调MFN1表达后,肝癌细胞的迁移和侵袭能力显著升高,MMP7的表达显著增加,而MMP1、MMP2与MMP9的表达无明显变化。结论:线粒体融合蛋白MFN1在肝癌转移组织中表达显著降低,可能通过激活MMP7表达,促进肝癌细胞侵袭和转移。     

lncRNA CEBPA-AS1靶向miR-455-3p调控胃癌细胞生物学行为的分子机制研究

摘要 目的：探讨lncRNA CEBPA-AS1对胃癌细胞生物学行为的影响及其可能作用机制。方法：qRT-PCR法检测胃癌组织、癌旁组织与正常人胃上皮GES1细胞和人胃癌SNU-1、AGS、HS-746T细胞系中lncRNA CEBPA-AS1、miR-455-3p的表达量。si-NC、si-lncRNA CEBPA-AS1、miR-NC、miR-455-3p mimics、si-lncRNA CEBPA-AS1与anti-miR-NC、si-lncRNA CEBPA-AS1与anti-miR-455-3p分别转染至SNU-1细胞（分别命名为si-NC组、si-lncRNA CEBPA-AS1组、miR-NC组、miR-455-3p组、si-lncRNA CEBPA-AS1+anti-miR-NC组和si-lncRNA CEBPA-AS1+anti-miR-455-3p组）后,MTT实验与平板克隆形成实验分别检测细胞增殖及克隆形成能力,Transwell小室实验检测细胞迁移及侵袭能力,双荧光素酶报告基因实验与qRT-PCR实验验证lncRNA CEBPA-AS1与miR-455-3p的靶向调控关系,Western blot法检测MMP2、MMP9蛋白表达情况。结果：与癌旁组织比较,胃癌组织中lncRNA CEBPA-AS1的表达量显著升高,miR-455-3p的表达量显著降低,差异均有统计学意义（均P＜0.05）。与GES1细胞比较,SNU-1、AGS、HS-746T细胞中lncRNA CEBPA-AS1的表达量显著升高,miR-455-3p的表达量显著降低,其中SNU-1细胞的lncRNA CEBPA-AS1表达量最高,差异均有统计学意义（均P＜0.05）。与si-NC组比较,si-lncRNA CEBPA-AS1组细胞活力降低,细胞克隆形成数、迁移及侵袭细胞数减少,MMP2、MMP9蛋白表达水平降低,差异均有统计学意义（P＜0.05）。与miR-NC组比较,miR-455-3p组细胞活力降低,细胞克隆形成数、迁移及侵袭细胞数减少,MMP2、MMP9蛋白表达水平降低,差异均有统计学意义（P＜0.05）。lncRNA CEBPA-AS1可靶向结合miR-455-3p,并可负调控miR-455-3p的表达。与si-lncRNA CEBPA-AS1+anti-miR-NC组比较,si-lncRNA CEBPA-AS1+anti-miR-455-3p组细胞活力升高,细胞克隆形成数、迁移及侵袭细胞数增多,MMP2、MMP9蛋白表达水平升高,差异均有统计学意义（P＜0.05）。结论：干扰lncRNA CEBPA-AS1表达可通过靶向调控miR-455-3p而抑制胃癌细胞增殖、克隆形成、迁移及侵袭。     

时钟基因Bmal1促进血管平滑肌细胞增殖

摘要 目的：观察时钟基因Bmal1的过表达对血管平滑肌细胞增殖的影响,进一步探讨生物节律对于血管发育的具体影响。方法：采用包装GV341-Bmal1载体的慢病毒转染的方法构建大鼠胸主动脉平滑肌细胞（A7R5）稳定转染Bmal1的细胞系,实时定量PCR和细胞爬片Bmal1的免疫荧光染色的方法判断所构建细胞系是否稳定过表达Bmal1,细胞爬片Ki67的免疫荧光染色的方法观察时钟基因Bmal1的过表达对血管平滑肌细胞增殖的影响。结果：实时定量PCR结果显示稳定转染Bmal1组细胞Bmal1的表达是对照组的11.2倍（P<0.01）;细胞爬片的免疫荧光染色结果显示稳定转染Bmal1组细胞BMAL1的表达明显升高（P<0.05）,且稳定转染Bmal1组Ki67阳性细胞比例明显升高（P<0.05）。结论：通过慢病毒转染的方法成功构建了血管平滑肌细胞稳定转染Bmal1的细胞系,细胞片Ki67的免疫荧光染色结果显示Bmal1的过表达促进了血管平滑肌细胞的增殖。     

BRCA1相关蛋白1对肾癌增殖和侵袭的实验研究

目的:研究BRCA1相关蛋白(BRCA1-associated protein-1,BAP1)对肾癌细胞增殖和侵袭的影响。方法:通过含有不同BAP1和HAT1载体的慢病毒感染后用嘌呤霉素筛选的方法在肾癌细胞系中构建BAP1稳定低表达、HAT1稳定高表达、HAT1稳定低表达以及BAP1低表达且HAT1低表达的慢病毒细胞稳转株。通过WB和PCR验证BAP1在肾癌细胞系中对于HAT1的调控。使用CCK-8细胞增殖和TRANSWELL侵袭实验检测对于肾癌细胞增殖和侵袭能力的影响。利用免疫组化和临床回访数据分析其临床意义。结果:肾癌细胞系中BAP1表达降低后HAT1表达升高。BAP1低表达部分通过了HAT1表达升高促进肾癌的增殖和侵袭能力。在肾癌组织中BAP1的表达与HAT1表达具有相关性(P0.05)。结论:BAP1敲低的肾癌细胞中HAT1特异性的高表达可能是导致肾癌细胞增殖和侵袭能力增强的原因。BAP1与HAT1在肾癌组织中的表达具有显著相关性。     

Nitrotyrosine promotes human aortic smooth muscle cell migration through oxidative stress and ERK1/2 activation

Nitrotyrosine is a new biomarker of atherosclerosis and inflammation. The objective of this study was to determine the direct effects of free nitrotyrosine on human aortic smooth muscle cell (AoSMC) migration and molecular mechanisms. By a modified Boyden chamber assay, nitrotyrosine significantly increased AoSMC migration in a concentration-dependent manner. For example, nitrotyrosine at 300 nM increased AoSMC migration up to 152% compared with l-tyrosine-treated control cells (P<0.01). Cell wound healing assay confirmed this effect. Nitrotyrosine significantly increased the expression of some key cell migration-related molecules including PDGF receptor-B, matrix metalloproteinase 2 (MMP2) and integrins alphaV and beta3 at both mRNA and protein levels in AoSMC (P<0.01). In addition, nitrotyrosine increased reactive oxygen species (ROS) production in AoSMC by staining with fluorescent dye DCFHDA. Furthermore, nitrotyrosine induced transient phosphorylation of ERK2 by Bio-Plex luminex immunoassay and western blot analysis. AoSMC were able to uptake nitrotyrosine. Antioxidants including seleno-l-methionine and superoxide dismutase mimetic (MnTBAP) as well as ERK1/2 inhibitor PD98059 effectively blocked the promoting effect of nitrotyrosine on AoSMC migration and the mRNA expression of above cell migration-related molecules. Thus, nitrotyrosine directly increases AoSMC migration in vitro and the expression of migration-related molecules through overproduction of ROS and activation of ERK1/2 pathway. Nitrotyrosine may contribute to cardiovascular pathogenesis.     

Investigation of Decitabine Effects on HDAC3 and HDAC7 mRNA Expression in NALM-6 and HL-60 Cancer Cell Lines

Background:Decitabine is a potent anticancer hypomethylating agent and changes the gene expression through the gene''s promoter demethylation and also independently from DNA demethylation. So, the present study was designed to distinguish whether Decitabine, in addition to inhibitory effects on DNA methyltransferase, can change HDAC3 and HDAC7 mRNA expression in NALM-6 and HL-60 cancer cell lines.Methods:HL-60, NALM-6, and normal cells were cultured, and the Decitabine treatment dose was obtained (1 µM) through the MTT assay. Finally, HDAC3 and HDAC7 mRNA expression were measured by Real-Time PCR in HL-60 and NALM-6 cancerous cells before and after treatment. Furthermore, HDAC3 and HDAC7 mRNA expression in untreated HL-60 and NALM-6 cancerous cells were compared to normal cells.Results:Our results revealed that the expression of HDAC3 and HDAC7 in HL-60 and NALM-6 cells increases as compared to normal cells. After treatment of HL-60 and NALM-6 cells with Decitabine, HDAC3, and HDAC7 mRNA expression were decreased significantly.Conclusion:Our data confirmed that the effects of Decitabine are not limited to direct hypomethylation of DNMTs, but it can indirectly affect other epigenetic factors, such as HDACs activity, through converging pathways.Key Words: Decitabine, HDAC3, HDAC7, HL-60, NALM-6     

Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models

Background

Compound targeting histone deacetylase (HDAC) represents a new era in molecular cancer therapeutics. However, effective HDAC inhibitors for the treatment of solid tumors remain to be developed.

Methodology/Principal Findings

Here, we propose a novel HDAC inhibitor, N-Hydroxy-4-(4-phenylbutyryl-amino) benzamide (HTPB), as a potential chemotherapeutic drug for solid tumors. The HDAC inhibition of HTPB was confirmed using HDAC activity assay. The antiproliferative and anti-migratory mechanisms of HTPB were investigated by cell proliferation, flow cytometry, DNA ladder, caspase activity, Rho activity, F-actin polymerization, and gelatin-zymography for matrix metalloproteinases (MMPs). Mice with tumor xenograft and experimental metastasis model were used to evaluate effects on tumor growth and metastasis. Our results indicated that HTPB was a pan-HDAC inhibitor in suppressing cell viability specifically of lung cancer cells but not of the normal lung cells. Upon HTPB treatment, cell cycle arrest was induced and subsequently led to mitochondria-mediated apoptosis. HTPB disrupted F-actin dynamics via downregulating RhoA activity. Moreover, HTPB inhibited activity of MMP2 and MMP9, reduced integrin-β1/focal adhesion complex formation and decreased pericellular poly-fibronectin assemblies. Finally, intraperitoneal injection or oral administration of HTPB efficiently inhibited A549 xenograft tumor growth in vivo without side effects. HTPB delayed lung metastasis of 4T1 mouse breast cancer cells. Acetylation of histone and non-histone proteins, induction of apoptotic-related proteins and de-phosphorylation of focal adhesion kinase were confirmed in treated mice.

Conclusions/Significance

These results suggested that intrinsic apoptotic pathway may involve in anti-tumor growth effects of HTPB in lung cancer cells. HTPB significantly suppresses tumor metastasis partly through inhibition of integrin-β1/FAK/MMP/RhoA/F-actin pathways. We have provided convincing preclinical evidence that HTPB is a potent HDAC targeted inhibitor and is thus a promising candidate for lung cancer chemotherapy.     

NOD1配体抑制人早孕期滋养细胞的侵袭功能

目的:明确固有免疫受体NOD1对人早孕期滋养细胞侵袭功能的调控及对侵袭相关因子分泌的影响。方法:采用免疫细胞化学法鉴定原代滋养细胞NOD1的表达,用transwell侵袭实验检测激活NOD1后滋养细胞侵袭功能的改变,ELISA检测配体刺激后滋养细胞MMP2和MMP9的分泌情况。结果:免疫细胞化学结果显示滋养细胞分离鉴定成功,且原代滋养细胞可以表达固有免疫受体NOD1。使用NOD1的特异性配体及非特异性配体,发现激活NOD1可以抑制滋养细胞的侵袭,且非特异性配体LPS可以下调侵袭相关金属基质蛋白酶分子MMP2和MMP9的分泌,特异性配体i E-DAP仅下调MMP9的分泌而对MMP2的分泌无影响。结论:固有免疫模式识别受体NOD1可以在早孕期滋养细胞表达,可调控滋养细胞的侵袭功能,其激活会导致侵袭相关分子MMP2和MMP9的分泌下降。